Advertisement
UK markets close in 2 hours 31 minutes
  • FTSE 100

    8,037.80
    +13.93 (+0.17%)
     
  • FTSE 250

    19,698.87
    +99.48 (+0.51%)
     
  • AIM

    753.25
    +4.07 (+0.54%)
     
  • GBP/EUR

    1.1611
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2391
    +0.0041 (+0.33%)
     
  • Bitcoin GBP

    53,341.46
    +122.58 (+0.23%)
     
  • CMC Crypto 200

    1,420.16
    +5.40 (+0.38%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    80.97
    -0.93 (-1.14%)
     
  • GOLD FUTURES

    2,323.80
    -22.60 (-0.96%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,055.47
    +194.67 (+1.09%)
     
  • CAC 40

    8,078.59
    +38.23 (+0.48%)
     

Novartis’s Stock Performance following the AveXis Agreement

Novartis’s Stock Performance following the AveXis Agreement

Novartis AG (NVS) announced an agreement and plan for a merger with AveXis on April 9, 2018. Following the recovery of major US indexes after the US-China trade war concerns—and also due to the announcement of the acquisition—Novartis AG’s ADR (American depositary receipt) reported a 1.1% rise in its price to close at $81.07 on April 9 compared to its previous close of $80.20 on April 6.